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RESOURCE USE AND COST DETERMINANTS FOR PATIENTS WITH CROHN’S
DISEASE IN A POLISH TERTIARY HOSPITAL
Petryszyn P, Dudkowiak R, Witczak I, Paradowski L
Wroclaw Medical University, Wroclaw, Poland
OBJECTIVES: To evaluate resource use and cost determinants associated with hospi-
talization of Crohn’s disease patients. METHODS: All patients hospitalized at our
institution from 01.01.2010 to 30.11.2011 were analyzed. We extracted all inpatient
records whose hospital discharge abstracts included ICD-10 code K50 consistent with
the diagnosis of Crohn’s disease. Statistical analysis was performed using the chi-
square test. RESULTS: Of 4028 all hospital admissions 315 belonged to Crohn’s dis-
ease. There were 150 females and 145 males, mean patient age was 37.8 years. 52
(16.5%) patients were hospitalized more than once therefore the total number of pa-
tients hospitalized was 220. The mean length of stay was 5.1 days. There were 42
hospitalizations in order to administer anti-TNF drug; these were excluded from fur-
ther analysis. The distribution of resource use was as follows: plain abdominal radio-
graph (6.2% of hospitalizations), small bowel pass through (5.9%), chest x-ray (36.3%),
abdominal ultrasound (76.6%), CT (13.9%), CT enteroclysis (25.3%), MRI (4.8%), upper
gastrointestinal endoscopy (52.7%), colonoscopy (55.7%). The drug usewas as follows:
sulfasalazine (22.3%),mesalamine (55.7%), azathioprine (26.7%), steroids (15.8%), anti-
biotics (23.8%). 11cases required totalparenteralnutrition.The lengthof stay, resource
anddruguseweredependentondiseaseactivity. 65.5%patientswithCRP10.0mg/dl
were hospitalized for not more than 5 days. Patients in whom antibiotics were used
accounted for 23.8% of cases and 40% of costs. CONCLUSIONS: The structure of
inpatient treatment costs for CD has been demonstrated for a Polish hospital.
Direct medical costs are in relation with disease activity.
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OBJECTIVES: PPIs are commonly used for GERD treatment, a condition character-
ized byheartburn and acid reflux symptoms. This study aimed to describe prescrib-
ing patterns, healthcare resource utilization, and PPI costs in a nationally repre-
sentative sample of GERD patients. METHODS: A nationally representative chart
review and patient/physician survey was conducted in GERD patients currently
taking a prescription PPI (esomeprazole-ESO, lansoprazole-LAN, omeprazole-OME,
dexlansoprazole-DEX, rabeprazole-RAB, pantoprazole-PAN). Physicians reported
their prescribing patterns in the past 6 months. Patient prescription information
and rationale for prescribing were also collected from charts. Annual PPI cost was
calculated by multiplying Red Book AWP by reported dose per day x 365.25.
RESULTS: 252 physicians [74 gastroenterologists (GEs), 178 primary care physicians
(PCP)] and 501 patients (94 ESO, 74 LAN, 94 OME, 94 DEX, 75 PAN, 70 RAB) were
included in the study. Patients were 51 years old on average, 37% male, with 16%
erosive versus 56% symptomatic GERD (28% undocumented). Physicians reported
most frequently prescribing OME (26.4% of their patients), with GEs more likely to
prescribe DEX (PCP 11%/GE 19%, p0.001) and RAB (PCP 9%/GE 13%, p0.01) and
PCPsmore likely to prescribeH2 blockers (PCP 12%/GE 7%). DEXwas the only PPI not
prescribed twice daily. 8%(PAN)-20%(OME) of other PPIs were used twice daily.
Moreover, all DEX patients were prescribed labeled doses, in contrast with other
PPIs prescribed at doses higher than labeled [6%(ESO)-37%(OME)]. Average annual
PPI costs ranged from $1600(DEX)-$3000(RAB), p0.001. There were no significant
differences in GERD-related hospitalizations, emergency room visits, or physician
visits across PPIs. CONCLUSIONS: Prescribing patterns varied greatly across PPIs.
While all included PPIs are labeled for once daily use, DEXwas observed as the only
PPI prescribed in full accord with the labeled doses and not prescribed twice daily
in our cohort. It also incurred lower medication costs compared to other PPIs.
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PREDICTORS OF NONPERSISTENCE AND NONADHERENCE WITH ORAL 5-
AMINOSALICYLIC ACID THERAPY IN PATIENTS WITH ULCERATIVE COLITIS
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OBJECTIVES: Assess risk factors associated with nonpersistence/nonadherence to
oral 5-aminosalicylic acid (5-ASA) medications in ulcerative colitis (UC) patients.
METHODS: IMS LifeLink™ Health Plan claims data 2007-2011 were analyzed to
identify patients 18 years with 1 UC diagnosis (ICD-9-CM: 556.x) and had 1
prescription for 5-ASA [balsalazide disodium, mesalamine delayed release, Multi-
Matrix System mesalamine (MMX), sulfasalazine] during the study period. 5-ASA
Medications nonpersistence/nonadherence following 12 months initial prescrip-
tion fill (indexmedication) were evaluated. Nonpersistence with indexmedication
was assessed for discontinuation (gap 60 days). Switch was identified if patients
changed to another product after discontinuing the index medication. Nonadher-
ence was determined bymedication possession ratio (MPR)0.8 for indexmedica-
tion, and proportion of days covered (PDC)0.8 for any 5-ASA. Coxmodel assessed
relative hazards associated with discontinuation. Logistic regression investigated
risk factors associated with nonadherence (PDC0.8). RESULTS: A total of 7608
patientsmet selection criteria. Themedian days to discontinuation differed signif-
icantly across index medications (range, 97 [sulfasalazine] to 175 days [MMX],
P0.0001). Patients on MMX were less likely to discontinue (75.3% vs 80.8%,
P0.0001), or switch (9.9% vs. 12%, P0.01), and more likely to adhere to their
medications (MPR0.8; 24.1% vs. 18.0%, P0.0001) than those on other medica-
tions. Major predictors of nonpersistence included index medication vs MMX (bal-
salazide disodium: HR1.18; mesalamine delayed release: HR1.23; sulfasalazine:
HR1.44), preferred provider organization (PPO) vs health maintenance organiza-
tion (HR1.10), and no prior use of immunosuppressive agents (HR1.26). Signifi-
cant variables associated with nonadherence included not switching medication
(OR2.03), residing in South versusMidwest region (OR1.42), never receiving spe-
cialist care (OR1.34), and Medicaid/Medicare versus commercial plan (OR1.44).
CONCLUSIONS: Patients on once-dailyMMXhad the lowest risk of discontinuation
and the highest adherence rate. Multiple factors including not using immunosup-
pressive agents, residing in South region, PPO plan, and non-commercial payer
were associated with nonpersistence/nonadherence with 5-ASAs.
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HOSPITALIZATION BURDEN OF GASTRO-INTESTINAL STROMAL TUMORS
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OBJECTIVES:Gastrointestinal Stromal Tumors (GISTs) arising from interstitial cells
of Cajal are known to result in significant healthcare utilization and costs. The
objective of this study was to determine hospitalization burden of GISTs, and as-
sess the factors predicting length of stay (LOS), total costs, and mortality among
individuals with GIST. METHODS: Data from the 2009 Nationwide Inpatient Sam-
ple were analyzed for the purpose of this study. Inpatient burden among individ-
uals with GIST (cases) were compared to those without any diagnosis of cancer
(controls) (case-control matched in 1:4 ratio). Multiple linear regression analysis
was used to determine the factors predicting LOS and total charges, and logistic
regression was used to determine predictors of mortality. RESULTS: In 2009, there
were a total of 14,562 hospitalizations among individuals with GIST in the United
States. Individualswith GIST had higher income, private insurance, identified from
teaching hospitals, higher LOS, higher total costs and higher number of diagnoses
as compared to controls. Individuals having income of $39,000–$47,999 (-
9,089.22; p0.005), individuals in rural hospitals (-13,443.01; p0.0001), increase
in LOS ($6,069.69; p0.0001) and increase in number of diagnoses ($1,008.35;
p0.03) were associated with higher total charges. Ages 35-49 (1.04; p0.04),
50-65 years (1.23; p0.03), 65-79 years (0.96; p0.03) and increase in number
of diagnoses (0.48; p0.0001) were associated with longer LOS among individu-
als with GIST. Rural hospitals (-1.02; p0.03) and patients who had a routine
discharge (-2.67; p0.0001) were associatedwith shorter LOS. Low income (Odds
Ratio [OR]2.36; p0.015), location of hospital in Midwest (OR2.17; p0.0001) and
increase in number of diagnoses (OR1.14; p0.0001) were associated with higher
odds of mortality among patients with GIST. CONCLUSIONS: The study highlights
the significant inpatient burden associated with GIST. Policy makers and health
care professionals could use these results to make appropriate health care deci-
sions aimed at improving outcomes in individuals with GIST.
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OBJECTIVES: Liver Diseases (LDs) are prevalent and generate high human and
economic costs to the society. Efficient strategies of diagnosis and treatment are
necessary to improve patients’ health and reduce costs. Our aim was to identify
healthcare quality indicators (HCQIs) to measure quality of care provided to LD
patients.METHODS: This work was conducted using a modified Delphi methodol-
ogy based on a two-stage rating process. We organized 7 expert panels, involving
8-10 hepatologists each. Each panel focused on one/few condition(s): hepatitis B,
hepatitis C, cirrhosis, hepatocellular carcinoma, autoimmune hepatopathies and
cholangiopathies, metabolic hepatopathies, liver transplant. For each condition a
preliminary set of HCQIs was identified and discussed by the panel, according to
evidence and experience. Then, each panelmember performed a first independent
rating of all HCQIs using the RAND 9-point agreement scale (RAS; 1totally dis-
agree to 9totally agree). Median scores of each HCQI were calculated and then
used to rate again the HCQIs in the light of these results. After this second rating, a
disagreement index (DI) was calculated to identify and accept (if DI1) indicators
with median RAS7. The final set of HCQIs was selected. RESULTS: The final list
included 8 valid HCQIs for hepatitis B, 7 for hepatitis C, 4 for compensated cirrhosis,
8 for decompensated cirrhosis, 10 for hepatocellular carcinoma, 12 for autoim-
mune hepatopathies and cholangiopathies, 11 for metabolic hepatopathies and 15
for liver transplant. Health-Related Quality-of-Life was included as a further HCQI
in all conditions. CONCLUSIONS:We identified and proposed a set of indicators as a
tool to assess the quality of care provided to patients affected with LDs. After a vali-
dation process, which is being performed, their use could help clinicians and budget
holders in understanding and improving the efficiency of the health care provided.
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